ABVX

Abivax
ABVX

$11.86

0.34%

Market Cap: 746M

About: Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Employees: 61

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 3 (+2) [Q1 2024]

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

40% more capital invested

Capital invested by funds: $239M [Q4 2023] → $334M (+$95.5M) [Q1 2024]

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

20% more funds holding

Funds holding: 30 [Q4 2023] → 36 (+6) [Q1 2024]

1.72% more ownership

Funds ownership: 35.43% [Q4 2023] → 37.15% (+1.72%) [Q1 2024]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$16

35%

upside

Avg. target

$38

218%

upside

High target

$50

322%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

BTIG Julian Harrison	263%upside $43	Buy Initiated	20 May 2024
Guggenheim Yatin Suneja	322%upside $50	Buy Initiated	29 Apr 2024
Piper Sandler Christopher Raymond	254%upside $42	Overweight Initiated	29 Apr 2024
Morgan Stanley Vikram Purohit	35%upside $16	Equal-Weight Maintained	11 Apr 2024

See Analyst Rankings

Financial journalist opinion

Abivax Provides Operational and Key Program Update

Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025 Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchanged Continued progress on pre-clinical combination therapy program Sylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy Officer Cash position allows for runway into Q4 2025 through ABTECT 8-week induction top-line results PARIS, France, July 15, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax”, “we” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today provided an update on the progress of key clinical and preclinical programs and its leadership and operational updates.

Abivax Provides Operational and Key Program Update

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the “General Meeting”), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax (“Board”).

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

ABIVAX Société Anonyme (OTC:AAVXF) Q4 2023 Earnings Conference Call April 8, 2024 8:30 AM ET Company Participants Patrick Malloy - SVP, IR Marc de Garidel - CEO Sheldon Sloan - Chief Medical Officer Didier Scherrer - Chief Scientific Officer Conference Call Participants Thomas Smith - Leerink Partners Vikram Purohit - Morgan Stanley Julian Harrison - BTIG Operator Ladies and gentlemen, thank you for standing by. Welcome to ABIVAX Conference Call to discuss 2023 Financial Results and Business Update.

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

Abivax reports 2023 financial results and operational update

Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global Market Sufficient funds to finance operations into Q4 2025, including through the announcement of top-line data from the Phase 3 ABTECT induction trials of obefazimod in ulcerative colitis (UC) Implementation of U.S. and European operational infrastructure to progress the Company's ongoing clinical and preclinical programs PARIS, France, April 2, 2024, 8:30 a.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2023 annual financial results, as of December 31, 2023, and provided an update on the progress of its development programs.

Abivax reports 2023 financial results and operational update

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (UC), will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 21-24, 2024, in Stockholm, Sweden. "We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

See News Rankings